BridgeBio Pharma BBIO Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's net income?
- BridgeBio Pharma (BBIO) reported net income of -$166.56M in Q1 2026.
- How has BridgeBio Pharma's net income changed year-over-year?
- BridgeBio Pharma's net income increased by 1.8% year-over-year, from -$169.61M to -$166.56M.
- What is the long-term trend for BridgeBio Pharma's net income?
- Over 4 years (2021 to 2025), BridgeBio Pharma's net income has grown at a 5.7% compound annual growth rate (CAGR), from -$586.45M to -$732.94M.
- What does net income mean?
- The company's total accounting profit or loss for the period.
- How do you interpret net income?
- An increase indicates improved profitability, while a decrease suggests rising costs or declining revenues.
- How does net income compare across companies?
- Standard across all public companies; biotech firms often show significant losses during R&D phases.